Cover Image
市場調查報告書

重症肌無力:開發平台分析

Myasthenia Gravis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200977
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
重症肌無力:開發平台分析 Myasthenia Gravis - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 110 Pages
簡介

重症肌無力是由於末梢神經的自體免疫性神經肌肉障礙,由於對尼古丁性乙醯膽鹼(ACh)突觸後受體的抗體,產生肌肉無力和易疲勞感的難治之症。由於肌肉無力,產生呼吸困難和咀嚼、吞嚥困難、頭部下垂、臉筋的脆弱化、嘶啞聲音、複視、眼瞼下垂等症狀。治療選項有,抑製自體免疫反應的醫藥品,及免疫球蛋白的靜脈注射等。

本報告提供全球各國的重症肌無力治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將其結果,為您概述為以下內容。

簡介

  • 分析範圍

重症肌無力概要

治療藥的開發

  • 重症肌無力開發中產品:概要
  • 重症肌無力開發中產品:比較分析

各企業開發中的重症肌無力治療藥

大學/研究機關研究中的重症肌無力治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

重症肌無力治療藥:開發中的產品一覽(各企業)

重症肌無力治療藥:研究中的產品一覽(各大學/研究機關)

重症肌無力開發治療藥的企業

  • Achillion Pharmaceuticals, Inc.
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • arGEN-X BV
  • Baxalta Incorporated
  • Biokine Therapeutics Ltd.
  • BioMarin Pharmaceutical Inc.
  • CuraVac, Inc.
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • HanAll Biopharma Co., Ltd.
  • Karus Therapeutics Limited
  • Lead Discovery Center GmbH
  • Neurotune AG
  • Novartis AG
  • Pfizer Inc.
  • ReceptoPharm, Inc.
  • Regenesance BV
  • Toleranzia AB

重症肌無力:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • amifampridine phosphate
  • ARGX-113
  • BB-008
  • belimumab
  • BKT-130
  • CFZ-533
  • Coversin
  • CVMG-01
  • eculizumab
  • GL-2045
  • HL-161
  • 免疫球蛋白(人類用)
  • KA-1463
  • 重症肌無力用 C1q 阻礙單株抗體
  • NT-1654
  • 重症肌無力用重組蛋白
  • regenemab
  • RPI-78M
  • SM-201
  • 自體免疫障礙、病毒感染用免疫蛋白酶體次單元LMP7阻礙小分子
  • 重症肌無力用補體D因素阻礙小分子
  • 重症肌無力用疫苗

重症肌無力治療藥:最新開發平台趨勢

重症肌無力治療藥:開發暫停的產品

重症肌無力治療藥:開發中止的產品

重症肌無力相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8981IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myasthenia Gravis - Overview
  • Myasthenia Gravis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Myasthenia Gravis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Myasthenia Gravis - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Alexion Pharmaceuticals Inc
    • Alpha Cancer Technologies Inc
    • Apellis Pharmaceuticals Inc
    • arGEN-X BV
    • BioMarin Pharmaceutical Inc
    • CuraVac Inc
    • GlaxoSmithKline Plc
    • Grifols SA
    • HanAll Biopharma Co Ltd
    • Karus Therapeutics Ltd
    • Millennium Pharmaceuticals Inc
    • Neurotune AG
    • Novartis AG
    • Pfizer Inc
    • Ra Pharmaceuticals Inc
    • Regenesance BV
    • Shire Plc
    • Toleranzia AB
    • UCB SA
  • Myasthenia Gravis - Drug Profiles
    • ACT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amifampridine phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFZ-533 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVMG-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methotrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Regenemab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rozanolixizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TK-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myasthenia Gravis - Dormant Projects
  • Myasthenia Gravis - Discontinued Products
  • Myasthenia Gravis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
      • Jan 06, 2017: argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
      • Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016
      • Dec 01, 2016: argenx to provide update on ARGX-113 during American Society of Hematology Annual Meeting
      • Sep 30, 2016: Toleranzia completes Eurostars project according to plan and postpones start of clinical study
      • Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York
      • Sep 02, 2016: Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis
      • Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress
      • Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
      • Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis
      • Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe
      • May 29, 2015: Double recognition of Toleranzia
      • Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis
      • Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
      • Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myasthenia Gravis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
  • Myasthenia Gravis - Pipeline by arGEN-X BV, H1 2017
  • Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
  • Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2017
  • Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Myasthenia Gravis - Pipeline by Grifols SA, H1 2017
  • Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Myasthenia Gravis - Pipeline by Karus Therapeutics Ltd, H1 2017
  • Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Neurotune AG, H1 2017
  • Myasthenia Gravis - Pipeline by Novartis AG, H1 2017
  • Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
  • Myasthenia Gravis - Pipeline by Regenesance BV, H1 2017
  • Myasthenia Gravis - Pipeline by Shire Plc, H1 2017
  • Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2017
  • Myasthenia Gravis - Pipeline by UCB SA, H1 2017
  • Myasthenia Gravis - Dormant Projects, H1 2017
  • Myasthenia Gravis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Myasthenia Gravis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top